BioAge Labs (NASDAQ:BIOA) Trading Down 8.7% – Time to Sell?

BioAge Labs, Inc. (NASDAQ:BIOA)’s share price was down 8.7% on Monday . The stock traded as low as $16.26 and last traded at $16.12. Approximately 107,037 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 621,039 shares. The stock had previously closed at $17.66.

Analysts Set New Price Targets

A number of research firms have commented on BIOA. BTIG Research initiated coverage on BioAge Labs in a research note on Wednesday, May 13th. They set a “buy” rating and a $40.00 price target on the stock. Oppenheimer started coverage on BioAge Labs in a research note on Wednesday, February 25th. They set an “outperform” rating and a $60.00 target price on the stock. Piper Sandler started coverage on shares of BioAge Labs in a research note on Tuesday, January 27th. They set an “overweight” rating on the stock. Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday. Finally, Morgan Stanley set a $23.00 target price on shares of BioAge Labs in a research note on Wednesday, February 4th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.00.

BioAge Labs Trading Down 12.5%

The company has a market cap of $686.53 million, a PE ratio of -6.44 and a beta of 0.99. The company has a fifty day simple moving average of $18.15 and a two-hundred day simple moving average of $15.88.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.19. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%.The business had revenue of $2.77 million during the quarter. On average, research analysts anticipate that BioAge Labs, Inc. will post -2.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BIOA. CWM LLC raised its holdings in shares of BioAge Labs by 39.9% in the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after purchasing an additional 1,053 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of BioAge Labs during the third quarter worth $27,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of BioAge Labs during the fourth quarter worth $77,000. Nisa Investment Advisors LLC increased its holdings in BioAge Labs by 4,219.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after buying an additional 10,000 shares during the last quarter. Finally, Bank of Nova Scotia acquired a new stake in BioAge Labs in the first quarter valued at $180,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.